Immunization against bacterial diseases of the intestine

Journal of Pediatric Gastroenterology and Nutrition

Volumn 31, Issue 4, 2000, Pages 336-355

  Levine, Myron M ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENGAL 15; BIVALENT O1 O139; CHOLERA VACCINE; CVD 112; CVD 908 HTR A; ENTEROTOXIN; ESCHERICHIA COLI VACCINE; O1 RBS WCV; PERU 15; SHIGA TOXIN; SHIGELLA VACCINE; TY800; TYPHOID VACCINE; X4073;

BACTERIAL INFECTION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG COST; HISTOPATHOLOGY; HUMAN; IMMUNIZATION; IMMUNOPATHOGENESIS; INFANT; INTESTINE INFECTION; MAJOR CLINICAL STUDY; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SALMONELLA ENTERICA; SHIGELLA; VIBRIO CHOLERAE;

BACTERIAL INFECTIONS; BACTERIAL VACCINES; CAMPYLOBACTER INFECTIONS; CHOLERA; DYSENTERY, BACILLARY; ESCHERICHIA COLI INFECTIONS; HELICOBACTER INFECTIONS; HUMANS; IMMUNIZATION; INTESTINAL DISEASES; INTESTINAL MUCOSA; INTESTINES; TYPHOID FEVER; VACCINES, ATTENUATED;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; SALMONELLA ENTERICA; SHIGELLA; VIBRIO CHOLERAE;

EID: 0033809199     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200010000-00003     Document Type: Review

References (213)

1. Modern vaccines. Enteric infections
2. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome
3. Investigational vaccine for Escherichia coli O157: Phase 1 study of O157 O-specific polysaccharide-Pseudomonas aemginosa recombinant exoprotein A conjugates in adults
4. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR
5. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains
6. Cholera
7. Escherichia coli that cause diarrhea: Enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent
8. Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains
9. Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypes
10. Shigella enterotoxin 1: An enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro
11. Effect of shigella enterotoxin 1 (ShET1. on rabbit intestine in vitro and in vivo
12. M cells as ports of entry for enteroinvasive pathogens: Mechanisms of interaction, consequences for the disease process
13. Microbial-host interactions at mucosal sites: Host response to pathogenic bacteria at mucosal sites
14. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development
15. The International Conference on Harmonization Good Clinical Practice guideline
16. Typhoid vaccines come of age
17. Vaccination against typhoid fever: Present status
18. Benign bacteremia caused by Salmonella typhi and paratyphi in children younger than 2 years
19. Typhoid fever in children aged less than 5 years
20. Salmonella typhi infection in children younger than five years of age
21. Multidrug-resistant typhoid in children: Presentation and clinical features
22. Multidrug-resistant Salmonella typhi: A worldwide epidemic
23. Constitutive expression of the phoP regulon attenuates Salmonella virulence and survival within macrophages
24. Characterization of defensin resistance phenotypes associated with mutations in the phoP-virulence regulon of salmonella-typhimurium
25. Reexamination of the protective role of the capsular polysaccharide Vi antigen of Salmonella typhi
26. Diagnostic value of the Widal test in areas endemic for typhoid fever
27. Typhoid fever vaccines
28. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi
29. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans
30. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: Three year results
31. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation
32. Comparison of enteric-coated capsules and liquid formulation of Ty21 a typhoid vaccine in randomised controlled field trial
33. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: A preliminary report
34. Protective activity of Vi polysaccharide vaccine against typhoid fever
35. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine
36. Duration of efficacy of ty21a, attenuated salmonella typhi live oral vaccine
37. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization
38. The human humoral immune response to Salmonella typhi Ty21a
39. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine
40. Vi capsular polysaccharideprotein conjugates for prevention of typhoid fever: Preparation, characterization, and immunogenicity in laboratory animals
41. Relation between structure and immunologic properties of the Vi capsular polysaccharide
42. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines
43. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam
44. Construction of genetically-defined double aro mutants of Salmonella typhi
45. Comparison of the safety and immunogenicity of aroC, aroD and cya,crp Salmonella typhi strains in adult volunteers
46. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain
47. Rubella viremia and antibody responses after rubella vaccination and reimmunization
48. Viremia in infants vaccinated with oral poliovirus vaccine (Sabin)
49. Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model
50. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors
51. Attenuated Salmonella typhi and Shigella as live oral vaccines and as live vectors
52. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans
53. Phase 2 clinical Trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. Volunteers
54. A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence
55. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers
56. Recombinant Salmonella vectors in vaccine development
57. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the ASD balanced lethal system
58. Progress in vaccines against typhoid fever
59. Vi serology in detection of chronic Salmonella typhi carriers in an endemic area
60. Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi careers
61. Chilean Typhoid Committee: Precise estimation of the numbers of chronic carders of Salmonella typhi in Santiago, chile, an endemic area
62. Characterization of defined ompR mutants of Salmonella typhi: ompR is involved in the regulation of Vi polysaccharide expression
63. The RcsB-RcsC regulatory system of Salmonella typhi differentially modulates the expression of invasion proteins, flagellin and Vi antigen in response to osmolarity
64. Virulence of B. typhosus and resistance to O antibody
65. The pathogenic and immunogenic activities of Salmonella typhi in relation to its antigenic constituents
66. Further observations on the properties of the Vi antigen of B. typhosus and its corresponding antibody
67. Role of the viaB locus in synthesis, transport and expression of Salmonella typhi Vi antigen
68. Characterization of the rcsA and rcsB genes from Salmonella typhi: rcsB through tviA is involved in regulation of Vi antigen synthesis
69. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar Typhi oral vaccine strain CVD 909
70. The global resurgence of cholera
71. Public health impact of Rwandan refugee crisis: What happened in Goma, Zaire, in July, 1994?
72. Characterization of phenotypic, serological, and toxigenic traits of Vibrio cholerae O139 bengal
73. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal
74. Immunity of cholera in man: Relative role of antibacterial versus antitoxic immunity
75. Volunteer studies in development of vaccines against cholera and enterotoxigenic Escherichia coli: A review
76. Duration of infection-derived immunity to cholera
77. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: Safety and efficacy against experimental challenge
78. Biotype as determinant of natural immunising effect of cholera
79. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients
80. A serological survey for cholera antibodies in rural east Pakistan: I. The distribution of antibody in the control population of a cholera vaccine field-trial area and the relation of antibody titer to the pattern of endemic cholera
81. Field trial of oral cholera vaccines in Bangladesh: Serum vibriocidal and antitoxic antibodies as markers of the risk of cholera
82. Seroepidemiological studies of El Tor cholera in Bangladesh: Association of serum antibody levels with protection
83. Toxin, toxincoregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans
84. Immunogenicity of Vibrio cholerae O1 toxin-coregulated pili in experimental and clinical cholera
85. An oral B subunit: Whole cell vaccine against cholera
86. Live oral cholera vaccine: From principle to product
87. Field trial of cholera vaccines in Bangladesh: Results from three year follow-up
88. Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a a basis for vaccine development
89. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits
90. Two year study of the protective efficacy of the oral whole cell plus recombinant B subunit (WC/rBS) cholera vaccine in Peru
91. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine
92. Construction of genetically marked Vibrio cholerae O1 vaccine strains
93. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR
94. Safety and im munogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: Results of a randomized, placebo-controlled, double-blind crossover trial
95. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults
96. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children
97. The safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine CVD 103-HgR in 24 to 59 month old Indonesian children
98. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults
99. Tolerancia e inmunogenicidad de una dosis oral de la cepa de Vibrio cholerae 01, viva-atenuada, CVD 103-HgR: Estudio de doble ciego en adultos Chilenos
100. Attenuated live oral cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O
101. Tolerancia, immunogenicidad, excresion y transmision de la vacuna anti-colera oral viva-atenuada, CVD 103-HgR, estudio pareado de doble ciego en ninos Chilenos de 24 a 59 meses
102. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers
103. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels
104. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and non-infected adults in Mali
105. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR
106. Live oral vaccines against cholera
107. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with vibrio cholerae O1 El tor Inaba three months after vaccination
108. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area
109. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand
110. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance
111. Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen O
112. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review
113. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants
114. Tropical enteropathy (environmental enteropathy) in early childhood: A syndrome caused by contaminated environment
115. Asymptomatic environmental enteropathy among slum-dwelling infants
116. Epidemiology of small bowel bacterial overgrowth and rice carbohydrate malabsorption in Burmese (Myanmar) village children
117. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR
118. Synergism between ecologic and immunologic control mechanisms of intestinal flora
119. Albendazole treatment of children with ascariasis enhances the vibriocidal response to the live attenuated oral cholera vaccine CVD 103-HgR
120. Effects of undernutrition on infection with Vibrio cholerae O1 and on response to oral cholera vaccine
121. Oral poliovirus vaccine: History of its development and prospects for eradication of poliomyelitis
122. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children
123. Safety and immunogenicity of Salmonella typhi Ty21a liquid forumlation vaccine in 4- to 6-year old Thai children
124. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1
125. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru
126. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype
127. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults
128. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines
129. Global burden of Shigella infections: Implications for vaccine development and implementation of control strategies
130. Inoculum size in shigellosis and implications for expected mode of transmission
131. Diarrheal disease during Operation Desert Shield
132. Diarrheal disease among military personnel during Operation Restore Hope, Somalia, 1992-1993
133. Epidemic Shigella dysenteriae type 1 in Burundi: Panresistance and implications for prevention
134. Pathophysiology of Shigella diarrhea in the rhesus monkey: Intestinal transport, morphological, and bacteriological studies
135. Molecular and cellular biology of Shigella flexneri invasiveness: From cell assay systems to shigellosis
136. Acute inflammation causes epithelial invasion and mucosal destruction in experimental shigellosis
137. Studies in volunteers to evaluate candidate Shigella vaccines: Further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease
138. Immunity in shigellosis: II. Protection induced by oral live vaccine or primary infection
139. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: Clinical experience and implications for Shigella infectivity
140. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in a poor periurban setting in Santiago, Chile
141. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei
142. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis
143. Sociodemographic factors associated with serum anti-Shigella lipopolysaccharide antibodies and shigellosis
144. Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide
145. Production of IFN-gamma and IL-10 to shigella invasins by mononuclear cells from volunteers orally inoculated with a shiga toxin-deleted shigella dysenteriae type 1 strain
146. Comparison of conjugates composed of lipopolysaccharide from Shigella flexneri type 2a detoxified by two methods and bound to tetanus toxoid
147. Polysaccharide-protein conjugates: A new generation of vaccines
148. Hypothesis for the vaccine development: Protective immunity to enteric diseases caused by non-typhoidal Salmonellae and Shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharides of their lipopolysaccharides
149. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults
150. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers
151. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children
152. Studies on vaccination against bacillary dysentery: 3. Effective oral immunization against Shigella flexneri 2a in a field trial
153. Studies on vaccination against bacillary dysentery: 4. Oral immunization with live monotypic and combined vaccines
154. Studies on vaccination against bacillary dysentery: 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains
155. Live oral Shigella vaccine: Vaccination schedule and the effect of booster dose
156. Shigellosis in custodial institutions: II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines
157. Shigellosis in custodial institutions. III. Prospective clinical and bacteriologic surveillance of children vaccinated with oral attenuated Shigella vaccine
158. Shigellosis in custodial institutions. IV. In vivo stability and transmissibility of oral attenuated streptomycin-dependent Shigella vaccines
159. Shigellosis in custodial institutions. V. Effect of intervention with streptomycin-dependent Shigella sonnei vaccine in an institution with endemic disease
160. Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: Implications for use of IpaC as a protein carrier
161. Immunogenicity of IpaC-hybrid proteins expressed in the Shigella flexneri 2a vaccine candidate SC602
162. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602
163. Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers
164. Construction and characterization of attenuated ΔaroA ΔvirG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine
165. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG
166. Engineered ΔguaB-A, ΔvirG Shigella flexneri 2a strain CVD 1205: Construction, safety, immunogenicity and potential efficacy as a mucosal vaccine
167. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans
168. Strategy for cross-protection among Shigella flexneri serotypes
169. Proteosomes for improved nasal oral or injectable vaccines
170. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models
171. Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines
172. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection
173. Optimism over vaccines administered via mucosal surfaces
174. Longitudinal studies of infectious diseases and physical growth in rural Bangladesh: II. Incidence of diarrhea and association with known pathogens
175. Colonization factors of human enterotoxigenic Escherichia coli (ETEC)
176. Fimbrial vaccines
177. Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic Escherichia coli
178. Enterotoxigenic Escherichia coli diarrhoea: Acquired immunity and transmission in an endemic area
179. Prevalence of toxin types and colonization factors in enterotoxigenic Escherichia coli isolated during a 2-year period from diarrheal patients in Bangladesh
180. Non-replicating whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: Stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes
181. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: Results of a large-scale field trial
182. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine
183. Oral inactivated vaccine against enterotoxigenic Escherichia coli
184. Intestinal irmnune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood
185. Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Egyptian adults
186. Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: Results of the initial evaluation in children. PRIDE Study Group
187. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants
188. Mutants of Escherichia coli heat-labile toxin lacldng ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
189. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
190. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
191. Evolutionary origin of pathogenic determinants in enterotoxigenic Escherichia coli and Vibrio cholerae O1
192. Analysis of antigenic determinants in cholera enterotoxin and heat-labile enterotoxins from human and porcine enterotoxigenic Escherichia coli
193. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: Application in serodiagnosis and seroepidemiology
194. Monoclonal antibodies with an expanded repertoire of specificities and potent neutralizing activity for Escherichia coli heat-labile enterotoxin
195. Attenuated Shigella flexneri 2a Vaccine Strain CVD 1204 expressing colonization factor antigen I (CFA/I. and mutant 'human' heat labile enterotoxin K63 of enterotoxigenic Escherichia coli
196. Simultaneous constitutive expression of CFA/I and CS3 colonization factors of enterotoxigenic Escherichia coli by aroC, aroD Salmonella typhi vaccine strain CVD 908
197. Further characterization of ΔaroA, ΔvirG Shigella flexrneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live vector vaccine for delivering antigens of enterotoxigenic Escherichia coli
198. Fimbriae (pili) adhesins as vaccines
199. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates
200. Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres
201. Immunisation of volunteers with a synthetic peptide vaccine for enterotoxigenic Escherichia coli
202. An inducible bundle-forming pilus of enteropathogenic Escherichia coli
203. A genetic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells
204. Attaching and effacing of host cells by enteropathogenic Escherichia coli in the absence of detectable tyrosine kinase mediated signal transduction
205. Experimental Campylobacter jejuni infection in humans
206. Vaccines against Campylobacter jejuni
207. Regulatory considerations for Campylobacter vaccine development
208. Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori
209. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers
210. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant
211. Cloning and sequencing of the genes for Shiga toxin from Shigella dysenteriae type 1
212. Shiga toxin: Biochemistry, genetics, mode of action, and role in pathogenesis